AMD Wins Outperform Rating and $600 Price Target on Doubling Data Center Revenue
Oppenheimer is citing strong data center momentum and projected 135% sales growth next year.
Already have an account? Sign in.
Oppenheimer is citing strong data center momentum and projected 135% sales growth next year.
Shares of Faeth Therapeutics plunged after Phase 2 endometrial cancer data hit the expected bar but failed to drive a re-rating of the stock.
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
Be the first to know when deals break, stocks move, or biotech headlines hit.